Avalyn Pharma Inc.
AVLN
$38.72
$2.145.84%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -43.31% | -53.51% | |||
| Total Depreciation and Amortization | 1,122.22% | 530.00% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 314.31% | 7,200.00% | |||
| Change in Net Operating Assets | 100.85% | -135.14% | |||
| Cash from Operations | -25.99% | -55.08% | |||
| Capital Expenditure | -- | -3,875.00% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -222.86% | 129.38% | |||
| Cash from Investing | -223.59% | 128.14% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 252.31% | -- | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 428.85% | 725.66% | |||